Oncolytic virus combined with traditional treatment versus traditional treatment alone in patients with cancer: a meta-analysis

Li, Yuwei; Shen, Yinan; Tang, Tianyu; Tang, Zengwei; Song, Wei; Yang, Zifan; Xiao-zhen, Zhang; Wang, Meng; Bai, Xueli; Liang, Tingbo

doi:10.1007/s10147-020-01760-4

Cited by 6 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Publication bias was tested using funnel plots. Publication bias was not necessary to perform if there were <10 included studies ( Li Y et al, 2020 ).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background: In recent years, several clinical trials have focused on oncolytic virus (OVs) combined with chemotherapy or immune checkpoint inhibitors (ICIs) in solid tumor patients, which showed encouraging effects. However, few studies have concentrated on the summary on the safety and efficacy of the combined treatments. Therefore, we conducted this meta-analysis to explore the safety and curative effect of the combined therapy.Methods: We searched the PubMed, Cochrane Library, Embase, and Clinicaltrials.gov databases to comprehensively select articles on OVs combined with chemotherapy or ICIs for the solid tumor treatment. Overall survival (OS), progression-free survival (PFS), 1-year survival rate, 2-year survival rate, objective response rate (ORR), and adverse events (AEs) were the outcomes.Results: Fifteen studies with 903 patients were included in this meta-analysis. The pooled ORR was 32% [95% confidence interval (CI): 27–36%, I2 = 24.9%, p = 0.239]. Median OS and median PFS were 6.79 months (CI: 4.29–9.30, I2 = 62.9%, p = 0.044) and 3.40 months (CI: 2.59–4.22, I2 = 0.0%, p = 0.715), respectively. The 1-year survival rate was 38% (CI: 0.29–0.47, I2 = 62.9%, p = 0.044), and the 2-year survival rate was 24% (CI: 12–37%, I2 = 0.0%, p = 0.805). The most common AEs were fever (63%, CI: 57–69%, I2 = 2.3%, p = 0.402), fatigue (58%, CI: 51–65%, I2 = 49.2%, p = 0.096), chill (52%, CI: 43–60%, I2 = 0.0%, p = 0.958), and neutropenia (53%, CI: 47–60%, I2 = 0.0%, p = 0.944).Conclusion: OVs combined with ICIs showed a better efficacy than OVs combined with chemotherapy, which lends support to further clinical trials of OVs combined with ICIs. In addition, OVs combined with pembrolizumab can exert increased safety and efficacy. The toxicity of grades ≥3 should be carefully monitored and observed. However, high-quality, large-scale clinical trials should be completed to further confirm the efficacy and safety of OVs combined with ICIs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/login.php], identifier [RD42022348568].

show abstract

“…Publication bias was tested using funnel plots. Publication bias was not necessary to perform if there were <10 included studies ( Li Y et al, 2020 ).…”

Section: Methodsmentioning

confidence: 99%

“…A meta-analysis by Li Y et al ( 2020 ) compared OVs combined with traditional treatment and traditional treatment alone in patients with cancer. However, we were unable to evaluate the effect of OVs combined with ICIs.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis of the efficacy and safety of oncolytic virus combination therapy, combination therapy improved objective response rates in lung cancer patients compared with conventional therapy alone [41] . OV is a particularly attractive option for preventing postoperative local recurrence and distant metastasis, and improving postoperative survival in lung cancer patients, they can directly target residual tumor deposits and beneficially modulate the postoperatively suppressed systemic immune environment [42] .…”

Section: Oncolytic Virus Combined With Standard Treatment Of Lung Cancermentioning

confidence: 99%

Lung cancer and oncolytic virotherapy——enemy's enemy

Zhang

et al. 2023

Translational Oncology

View full text Add to dashboard Cite

“…It has been shown that OVs can improve T-cell infiltration (Ribas et al 2017 ) and significantly improve the effectiveness of traditional therapies (Li et al 2020 ). They can also be usefully integrated into other tumor immunotherapies (Bommareddy et al 2018 ) and even induce therapeutic response in cancer refractory to ICIs (Bommareddy et al 2019 ).…”

Section: Therapies That Remodel the Inflammatory And Immune Responsementioning

confidence: 99%

“…Despite all the challenges, such as decreased immunogenicity and difficulties in delivery to the tumor site, they constitute a promising therapeutic strategy Sahin and Tureci ( 2018 ), Wen et al ( 2019 ), Thomas and Prendergast ( 2016 ), Morse et al ( 2021 ), Bowen et al ( 2018 ), Wang et al ( 2018 ) Oncolytic viruses Oncolytic viruses target tumor, but do not attack healthy cells. They replicate in the cancer cells, leading to their damage and activate inflammatory anti-tumor response, which can prevent cancer progression and also contribute to the effectiveness of other treatment strategies Marelli et al ( 2018 ), Guo et al ( 2017 ), Everts et al ( 2020 ), Tysome et al ( 2012 ), Ribas et al ( 2017 ), Li et al ( 2020 ), Bommareddy et al ( 2018 , 2019 ) Radiotherapy Radiotherapy has a great influence on the anti-cancer immune response, but the balance between stimulation of the immune activity and immunosuppression is very delicate. Radiation can kill cancer cells and aid in tumor regression, but in other circumstances, it promotes unwanted changes in the TME McLaughlin et al ( 2020 ), Rodriguez-Ruiz et al ( 2018 ), Koller et al ( 2017 ), Wang et al ( 2019a ), Jarosz-Biej et al ( 2019 ) Chimeric antigen receptor T cells CAR T cells are genetically altered patient’s own T cells, which are able to bind tumor antigens in an MHC-independent manner, which results in activation strengthened by additional intracellular domains.…”

Section: Therapies That Remodel the Inflammatory And Immune Responsementioning

confidence: 99%

Cancer-associated inflammation: pathophysiology and clinical significance

Pęczek

Gajda

Rutkowski

et al. 2022

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose Cancer cells, despite stemming from the own cells of their host, usually elicit an immune response. This response usually enables elimination of cancer at its earliest stages. However, some tumors develop mechanisms of escaping immune destruction and even profiting from tumor-derived inflammation. Methods We summarized the roles of different immune cell populations in various processes associated with cancer progression and possible methods of reshaping tumor-associated inflammation to increase the efficacy of cancer therapy. Results Changes in various signaling pathways result in attraction of immunosuppressive, pro-tumorigenic cells, such as myeloid-derived suppressor cells, tumor-associated macrophages, and neutrophils, while at the same time suppressing the activity of lymphocytes, which have the potential of destroying cancer cells. These changes promote tumor progression by increasing angiogenesis and growth, accelerating metastasis, and impairing drug delivery to the tumor site. Conclusion Due to its multi-faceted role in cancer, tumor-associated inflammation can serve as a valuable therapy target. By increasing it, whether through decreasing overall immunosuppression with immune checkpoint inhibitor therapy or through more specific methods, such as cancer vaccines, oncolytic viruses, or chimeric antigen receptor T cells, cancer-derived immunosuppression can be overcome, resulting in immune system destroying cancer cells. Even changes occurring in the microbiota can influence the shape of antitumor response, which could provide new attractive diagnostic or therapeutic methods. Interestingly, also decreasing the distorted tumor-associated inflammation with non-steroidal anti-inflammatory drugs can lead to positive outcomes.

show abstract

Oncolytic virus combined with traditional treatment versus traditional treatment alone in patients with cancer: a meta-analysis

Cited by 6 publications

References 27 publications

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis

Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis

Lung cancer and oncolytic virotherapy——enemy's enemy

Cancer-associated inflammation: pathophysiology and clinical significance

Contact Info

Product

Resources

About